Boston Trust Walden Corp Trims Holdings in Stryker Corporation $SYK

Boston Trust Walden Corp reduced its stake in Stryker Corporation (NYSE:SYK) by 0.6% during the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 280,004 shares of the medical technology company’s stock after selling 1,797 shares during the quarter. Boston Trust Walden Corp owned 0.07% of Stryker worth $92,007,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in the stock. Godfrey Financial Associates Inc. purchased a new stake in Stryker during the fourth quarter worth about $26,000. Sankala Group LLC purchased a new position in shares of Stryker in the fourth quarter valued at approximately $26,000. United Financial Planning Group LLC purchased a new position in shares of Stryker in the third quarter valued at approximately $27,000. Atlas Capital Advisors Inc. acquired a new position in shares of Stryker in the fourth quarter valued at approximately $27,000. Finally, DJE Kapital AG acquired a new position in shares of Stryker in the fourth quarter valued at approximately $28,000. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have commented on the stock. BTIG Research decreased their price target on shares of Stryker from $397.00 to $379.00 and set a “buy” rating for the company in a research report on Friday, May 1st. Weiss Ratings cut Stryker from a “hold (c+)” rating to a “hold (c)” rating in a research note on Monday, May 4th. Citigroup cut their price target on Stryker from $420.00 to $385.00 and set a “buy” rating on the stock in a report on Tuesday, April 7th. Evercore set a $355.00 price target on Stryker in a research report on Friday, May 1st. Finally, Deutsche Bank Aktiengesellschaft set a $315.00 price objective on Stryker in a research note on Friday, May 1st. Sixteen investment analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $395.33.

Insiders Place Their Bets

In related news, VP Robert S. Fletcher sold 4,544 shares of the stock in a transaction on Thursday, May 28th. The shares were sold at an average price of $306.87, for a total value of $1,394,417.28. Following the transaction, the vice president directly owned 10,582 shares of the company’s stock, valued at $3,247,298.34. This trade represents a 30.04% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Ronda E. Stryker sold 310,000 shares of Stryker stock in a transaction on Tuesday, May 26th. The stock was sold at an average price of $312.23, for a total transaction of $96,791,300.00. Following the sale, the director owned 1,924,880 shares in the company, valued at $601,005,282.40. This represents a 13.87% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 323,264 shares of company stock valued at $100,659,489. 4.60% of the stock is owned by corporate insiders.

Stryker Stock Performance

Shares of SYK stock opened at $326.41 on Friday. The company has a current ratio of 2.11, a quick ratio of 1.25 and a debt-to-equity ratio of 0.62. The firm has a fifty day moving average price of $309.86 and a 200 day moving average price of $338.96. The company has a market cap of $125.13 billion, a P/E ratio of 37.78, a PEG ratio of 2.01 and a beta of 0.77. Stryker Corporation has a 12 month low of $281.00 and a 12 month high of $404.87.

Stryker (NYSE:SYK) last posted its quarterly earnings results on Thursday, April 30th. The medical technology company reported $2.60 earnings per share for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.38). The business had revenue of $6.02 billion during the quarter, compared to analyst estimates of $6.34 billion. Stryker had a net margin of 13.20% and a return on equity of 23.42%. The firm’s quarterly revenue was up 2.6% on a year-over-year basis. During the same quarter in the prior year, the business earned $2.84 earnings per share. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. Sell-side analysts predict that Stryker Corporation will post 14.98 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Tuesday, June 30th will be issued a dividend of $0.88 per share. The ex-dividend date of this dividend is Tuesday, June 30th. This represents a $3.52 dividend on an annualized basis and a yield of 1.1%. Stryker’s dividend payout ratio (DPR) is presently 40.74%.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.